Scandion Oncology A/S (SCOL.ST) Research

Operating as a clinical-stage biotechnology company, Scandion Oncology A/S specializes in creating pharmaceutical solutions to combat resistance to chemotherapy. Their primary investigational drug, SCO-101, an orally administered compound, is currently progressing through Phase Ib and Phase II clinical studies with cancer patients. Another pipeline candidate, SCO-201, is undergoing preclinical assessment for its potential efficacy against solid tumors. Established in 2017, Scandion Oncology A/S maintains its headquarters in Copenhagen, Denmark.

Market snapshot

Symbol
SCOL.ST
Price
$0.00
Day change
-39.71%
Market cap
$654.0K
P/E ratio
-0.01x
52-week range
0.0037-0.179
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST)
  • FluoGuide A/S (FLUO.ST)
  • Hansa Biopharma AB (publ) (HNSA.ST)
  • Oncopeptides AB (publ) (ONCO.ST)
  • Saniona AB (publ) (SANION.ST)

Open Scandion Oncology A/S (SCOL.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.